Latest Sanofi Stories
PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(®) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study
-- Real World Outcome Study of Patients with Type 2 Diabetes Presented at American Diabetes Association 74th Scientific Sessions -- BRIDGEWATER, N.J., June 14, 2014 /PRNewswire/ --
SCRS Welcomes INC Research, inVentiv Health, Novartis and Sanofi ELLICOTT CITY, Md., June 13, 2014 /PRNewswire/ -- Leading sponsor and CRO organizations continue to join the Society
DALLAS, June 13, 2014 /PRNewswire/ -- MarketReportsChina.com adds "Research on China Cardiovascular Drugs Industry, 2014-2018" market intelligence report of 85 pages to
Both doses of investigational drug sarilumab met all three co-primary endpoints PARIS and TARRYTOWN, N.Y., June 12, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY)
SAN FRANCISCO, June 11, 2014 /PRNewswire/ -- Kindred Biosciences, Inc.
- Veteran of animal health brings depth of expertise to Merial's R&D organization - LYON, France, June 10, 2014 /PRNewswire/ -- Merial, the animal health division of Sanofi, today
MONTREAL, June 4, 2014 /CNW Telbec/ - A Canadian study has identified a new strategy for improving the care of patients living with Type 2 Diabetes (T2D) by empowering them to manage their own
Dr. Kongsamut specializes in age-related and neuroscience/CNS disorders PLANTATION, Fla., June 4, 2014 /PRNewswire/ -- Neurotrope, Inc.
Companies anticipate providing over-the-counter (OTC) product to treat erectile dysfunction after expiration of certain patents PARIS and INDIANAPOLIS, May 28, 2014 /PRNewswire/ -- Sanofi (EURONEXT:
- A trick or prank.